参考文献/References:
[1] BENGOECHEA J A, SA PESSOA J. Klebsiellapneumoniae infection biology: living to counteracthost defences[J]. FEMS Microbiology Reviews, 2019,43(2): 123-144.
[2] GU Danxia, DONG Ning, CHEN Sheng, et al. A fataloutbreak of ST11 carbapenem-resistant hypervirulentKlebsiella pneumoniae in a Chinese hospital:a molecular epidemiological study[J]. Lancet Infectious Diseases, 2018, 18(1): 37-46.
[3] PATEL P K, RUSSO T A, KARCHMER A W.Hypervirulent Klebsiella pneumoniae[J]. Open ForumInfect Dis, 2014,1(1): ofu028.
[4] ZHOU Yun, WANG Xing, SHEN Jun, et al. Endogenous endophthalmitis caused by carbapenem-resistanthypervirulent Klebsiella pneumoniae: A case report andliterature review [J]. Ocular Immunology and Inflammation, 2019, 27(7): 1099-1104.
[5] SHON A S, BAJWA R P, RUSSO T A. Hypervirulent(hypermucoviscous) Klebsiella pneumoniae: a new anddangerous breed[J]. Virulence, 2013, 4(2): 107-118.
[6] ZHOU Kai, XIAO Tingting, DAVID S, et al.Novel subclone of carbapenem-resistant Klebsiellapneumoniae sequence type 11 with enhanced virulenceand transmissibility, China [J]. Emerging InfectiousDiseases, 2020, 26(2): 289-297.
[7] KARAH N, SUNDSFJORD A, TOWNER K, et al.Insights into the global molecular epidemiology ofcarbapenem non-susceptible clones of Acinetobacterbaumannii[J]. Drug Resistance Updates, 2012, 15(4):237-247.
[8] SOHEI H，YOHEI D. Hypervirulent Klebsiellapneumoniae: a call for consensus definition andinternational collaboration [J].Journal of ClinicalMicrobiology, 2018, 56(9): e00959-18.
[9] RUSSO T A, MARR C M. Hypervirulent Klebsiellapneumoniae[J]. Clinical Microbiology Reviews, 2019,32(3): e00001-e00019.
[10] 黎斌斌 , 刘颖梅 , 王春雷 , 等 . 肺炎克雷伯菌血流感染的临床及分子特征 [J]. 中华检验医学杂志 , 2015,38(9):627-631. LI Binbin, LIU Yingmei,WANG Chunlei,et al. Clinicaland molecular characteristics of bloodstream infectioncaused by K. pneumonia [J]. Chinese Journal ofLaboratory Medicine,2015,38（9）:627-631.
[11] LAM M, WYRES L, DUCHENE S, et al. Populationgenomics of hypervirulent Klebsiella pneumoniaeclonal-group 23 reveals early emergence and rapidglobal dissemination[J]. Nature Communications, 2018,9(1): 2703.
[12] ZHAN Lingling,WANG Shanshan,GUO Yinjuan,et al.Outbreak by hypermucoviscous Klebsiella pneumoniaeST11 isolates with carbapenem resistance in a tertiaryhospital in China[J]. Frontiers in Cellular and InfectionMicrobiology, 2017, 7: 182.
[13] WONG M H Y, SHUM H P, CHEN J H K, et al.Emergence of carbapenem-resistant hypervirulentKlebsiella pneumoniae[J].The Lancet InfectiousDiseases, 2018, 18(1): 24.
[14] LEE C R,LEE J H, PARK K S, et al. Antimicrobialresistance of hypervirulent Klebsiella pneumoniae: Epidemiology, Hypervirulence-Associated Determinants,and Resistance Mechanisms[J].Front Cell Infect Microbiol ,2017 ,7:483.
[15] SIU L K, HUANG D B, CHIANG T. Plasmidtransferability of KPC into a virulent K2 serotypeKlebsiella pneumoniae[J]. BMC Infectious Diseases,2014, 14: 176.
[16] DONG Ning, LIN Dachuan, ZHANG Rong, et al.Carriage of blaKPC-2 by a virulence plasmid inhypervirulent Klebsiella pneumoniae[J]. the Journalof Antimicrobial Chemotherapy, 2018, 73(12): 3317-3321.
[17] TOLEDO P V M, ARANHA J A A, AREND L N, et al.Activity of antimicrobial combinations against KPC2-producing Klebsiella pneumoniae in a rat modeland time-kill assay[J]. Antimicrobial Agents andChemotherapy, 2015, 59(7): 4301-4304.
[18] ZHANG Jisheng,YU Lan,FU Yanjun,et al.Tigecyclinein combination with other antibiotics against clinicalisolates of carbapenem-resistant Klebsiella pneumoniaein vitro[J]. Annals of Palliative Medicine, 2019, 8(5):622-631.
[19] DUNDAR D, DUYMAZ Z, GENC S, et al. In-vitroactivities of imipenem-colistin, imipenem-tigecycline,and tigecycline-colistin combinations againstcarbapenem-resistant Enterobacteriaceae[J]. Journalof Chemotherapy (Florence, Italy), 2018, 30(6/8): 342-347.
[20] POURNARAS S, VRIONI G, NEOU E, et al. Activityof tigecycline alone and in combination with colistinand meropenem against Klebsiella pneumoniaecarbapenemase (KPC)-producing Enterobacteriaceaestrains by time-kill assay[J]. International Journal ofAntimicrobial Agents, 2011, 37(3): 244-247.
[21] MORICI P, FLORIO W, RIZZATO C, et al. Synergisticactivity of synthetic N-terminal peptide of humanlactoferrin in combination with various antibioticsagainst carbapenem-resistant Klebsiella pneumoniaestrains[J]. European Journal of Clinical Microbiology& Infectious Diseases, 2017, 36(10): 1739-1748.
[22] YU Wei, SHEN Ping, BAO Zhang, et al. In vitroantibacterial activity of fosfomycin combined withother antimicrobials against KPC-producing Klebsiellapneumoniae[J]. International Journal of AntimicrobialAgents, 2017, 50(2): 237-241.
[23] NI Wentao, LI Guobao, ZHAO Jin, et al. Use of montecarlo simulation to evaluate the efficacy of tigecycline and minocycline for the treatment of pneumonia due tocarbapenemase-producing Klebsiella pneumoniae[J].Infectious Diseases (London, England), 2018, 50(7):507-513.
[24] DU Xiaoxing, HE Fang, SHI Qiucheng, et al. Therapid emergence of tigecycline resistance in bla KPC-2harboring Klebsiella pneumoniae, as mediated in vivoby mutation in teta during tigecycline treatment[J].Front Microbiol ,2018,9:648.
[25] LIU Yiyun, WANG Yang, WALSH T R, et al.Emergence of plasmid-mediated colistin resistancemechanism MCR-1 in animals and human beings inChina: a microbiological and molecular biologicalstudy[J]. The Lancet Infectious Diseases, 2016, 16(2):161-168.
[26] GHAFUR A, DEVARAJAN V, RAJA T, et al.Monotherapy versus combination therapy againstnonbacteremic carbapenem-resistant gram-negativeinfections: a retrospective observational study[J]. IndianJournal of Critical Care Medicine : Peer-reviewed,2017, 21(12): 825-829.
相似文献/References:
[1]王 琪,胡燕燕,张 嵘,等.临床常见革兰阴性杆菌对替加环素的药敏情况分析[J].现代检验医学杂志,2016,31(01):8.[doi:10.3969/j.issn.1671-7414.2016.01.003]
WANG Qi,HU Yan-yan,ZHANG Rong,et al.Resistance of Clinical Isolated Gram
Negative Bacilli to Tigecycline[J].Journal of Modern Laboratory Medicine,2016,31(03):8.[doi:10.3969/j.issn.1671-7414.2016.01.003]
[2]张 华,詹 颉,苍金荣,等.TGC,MH和PB对泛耐药鲍曼不动杆菌的体外抗菌活性观察[J].现代检验医学杂志,2015,30(04):93.[doi:10.3969/j.issn.1671-7414.2015.04.026]
ZHANG Hua,ZHAN Jie,CANG Jin-rong,et al.Antibacterial Activity Observation of TGC,
MH and PB on the Pan-resistant Acinetobacter Baumannii in Vitro[J].Journal of Modern Laboratory Medicine,2015,30(03):93.[doi:10.3969/j.issn.1671-7414.2015.04.026]
[3]代鑫露,黄松音,李红玉.三种方法评估替加环素对多重耐药鲍曼不动杆菌体外药敏结果分析[J].现代检验医学杂志,2020,35(03):103.[doi:10.3969/j.issn.1671-7414.2020.03.027]
DAI Xin-lu,HUANG Song-yin,LI Hong-yu.Comparision of Three Susceptibility Testing Methods of Tigecycline Against
Multidrug Resistant Acinetobacter Baumannii[J].Journal of Modern Laboratory Medicine,2020,35(03):103.[doi:10.3969/j.issn.1671-7414.2020.03.027]